Lymphoma vs leukemia
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive content from multiple authoritative textbooks. Let me compile the full comparison.
Lymphoma vs. Leukemia: A Comprehensive Comparison
These two diseases are both hematologic (blood cell) malignancies arising from the same family of cells - lymphoid and myeloid progenitors - but they differ fundamentally in where the cancer originates, how it grows, and how it presents clinically.
The Core Distinction
| Feature | Leukemia | Lymphoma |
|---|---|---|
| Primary site | Bone marrow | Lymph nodes / lymphoid tissue |
| Blood involvement | Malignant cells flood the bloodstream | Usually confined to lymphoid tissue (initially) |
| Main cell in peripheral blood | Leukemic blasts / abnormal WBCs | Usually absent (except in advanced disease) |
| Presentation | Cytopenias (anemia, infections, bleeding) | Lymphadenopathy, B symptoms, mass |
Leukemia
Leukemia is a malignancy arising in the bone marrow, where abnormal (clonal) white blood cell precursors accumulate and crowd out normal hematopoiesis. The loss of normal marrow function produces the classic clinical triad of:
- Anemia (fatigue, pallor)
- Neutropenia (susceptibility to infections)
- Thrombocytopenia (bleeding, bruising)
As disease progresses, leukemic blasts "pour out into the bloodstream and eventually occupy the lymph nodes, spleen, and other organs." If untreated, acute leukemia is rapidly fatal, with most patients dying within months. - Goldman-Cecil Medicine, p. 2019
Types of Leukemia
| Type | Key Features |
|---|---|
| ALL (Acute Lymphoblastic) | Most common cancer in children <15 yrs; peak age 2-10 yrs; lymph node/spleen enlargement common; mediastinal mass in T-ALL |
| AML (Acute Myeloid) | Median age ~67 yrs; most common acute leukemia in adults; ~20,000 new US cases/year |
| CLL (Chronic Lymphocytic) | Most common leukemia in the US; mature-appearing B lymphocytes accumulate in blood, bone marrow, spleen, and lymph nodes |
| CML (Chronic Myeloid) | Driven by BCR-ABL1 fusion (Philadelphia chromosome); indolent course until blast crisis |
CLL is a special bridge case: CLL is characterized by the accumulation of mature-appearing B lymphocytes in the circulating blood, bone marrow, spleen, and multiple lymph nodes - it behaves like both a leukemia and a lymphoma. - Textbook of Family Medicine, 9e
Key Lab Finding
- Peripheral blood smear: blasts, lymphocytosis
- Bone marrow biopsy: >20% blasts (for acute leukemia diagnosis)
Lymphoma
Lymphoma is a malignancy arising in lymphoid tissue (primarily lymph nodes, but also spleen, thymus, and extranodal sites). The tumor mass grows as a solid tumor within lymph nodes; leukemic spill into the blood is not a defining feature early on.
There are two major categories:
1. Hodgkin Lymphoma (HL)
- ~10-15% of all lymphomas
- Hallmark cell: the Reed-Sternberg (RS) cell - a large (~45 µm) cell with multiple nuclei or multilobed nucleus, each with a prominent inclusion-like nucleolus (5-7 µm, the size of a small lymphocyte). - Robbins Pathology, p. 3834
- RS cells arise from germinal center B cells with clonal IGH gene rearrangements
- Over 90% of the cellular content is reactive immune cells (lymphocytes, histiocytes, plasma cells, neutrophils) - the RS cells are actually a minority
- RS cells activate NF-κB (via EBV's LMP-1 protein or IκB mutations), which rescues "crippled" germinal center B cells from apoptosis
- RS cells overexpress PD-L1/PD-L2, neutralizing cytotoxic T-cell responses
- Nodular sclerosis is the most common subtype (coarse collagen bands, lacunar RS cell variants)
- CD markers: Classic HL - CD30+, CD15+, CD20-; Nodular lymphocyte-predominant HL - CD20+, CD30-, CD15-
- Staging: Ann Arbor staging based on location and number of lymph node regions involved
2. Non-Hodgkin Lymphoma (NHL)
- ~85-90% of all lymphomas
- 85-90% are B-cell origin in the US and Europe
- Much more heterogeneous than HL
Common NHL subtypes (from Goldman-Cecil):
| Subtype | Frequency | Key Features |
|---|---|---|
| Diffuse Large B-cell (DLBCL) | ~30% of all NHL | Most common; aggressive; CD19+, CD20+, CD22+, CD79a+ |
| Follicular Lymphoma | ~20% of all NHL | Indolent; germinal center B cells; most common in Western countries |
| Mantle Cell Lymphoma | Less common | CD5+, cyclin D1+, SOX11+; aggressive |
| Burkitt Lymphoma | Rare; very aggressive | MYC translocation; extremely rapid tumor growth |
| T-cell / NK-cell lymphomas | ~10-15% | Diverse; angioimmunoblastic T-cell lymphoma can cause chronic polyarthritis + erythroderma |
Biopsy note: FNA has ~90% accuracy for metastatic carcinoma but is less sensitive for lymphoma - core-needle or excisional biopsy is preferred, especially for HL where RS cell identification is essential. - Sabiston Surgery
The Overlap Zone: Lymphoblastic Leukemia/Lymphoma
This is a critical concept where the two conditions blur. B-lymphoblastic leukemia/lymphoma (B-ALL/LBL) and T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) are considered the same disease at different ends of a spectrum:
-
When disease is predominantly in the bone marrow/blood → called leukemia
-
When disease is predominantly in lymph nodes/tissue mass with <25% bone marrow involvement → called lymphoma
-
Both express TdT (terminal deoxynucleotidyl transferase), a key marker
-
B-ALL/LBL: CD19+, CD79a+, CD10+, CD22+, CD20+
-
T-ALL/LBL: CD7+, CD52+, CD32+; often presents as a mediastinal mass
-
Sabiston Surgery, p. 1675
Clinical Presentation Summary
| Feature | Leukemia | Lymphoma |
|---|---|---|
| Lymphadenopathy | Can occur (esp. ALL, CLL) | Primary finding |
| Splenomegaly | Common | Common |
| B symptoms (fever, night sweats, weight loss) | Less classic | Prominent in HL and aggressive NHL |
| Bone pain | Very common (subperiosteal infiltration; 10-50% of patients) | Less common |
| Articular symptoms | Common (14-50% children, 4-16% adults with acute leukemia) | 25% of NHL patients |
| Mediastinal mass | T-ALL | Hodgkin HL (nodular sclerosis), T-LBL |
| CNS involvement | ALL (requires intrathecal prophylaxis) | CNS lymphoma (rare but serious) |
| CBC | Leukocytosis, blasts on smear, cytopenias | Usually normal early; pancytopenia if marrow infiltrated |
Treatment Overview
| Leukemia | Lymphoma | |
|---|---|---|
| Acute | Intensive induction chemotherapy (e.g., "7+3" for AML; VXLD for ALL) + intrathecal CNS prophylaxis | RCHOP for DLBCL; ABVD for HL |
| Chronic | TKIs (imatinib for CML); chemoimmunotherapy for CLL | Watch-and-wait for indolent; CAR-T for relapsed/refractory |
| Targeted | Venetoclax, FLT3 inhibitors, IDH inhibitors | Anti-CD20 (rituximab), anti-CD30, checkpoint inhibitors (HL) |
| Curative potential | ALL in children (~90% cure rate); AML with HCT | HL (~85-90% cure); aggressive NHL with R-CHOP |
Memory Hook
- "Leuka" = white (blood) - the cancer is in the blood and bone marrow; you diagnose it with a CBC and bone marrow biopsy
- "Lymph-oma" = tumor of lymph - the cancer forms a mass in lymph nodes; you diagnose it with a lymph node biopsy
- CLL/SLL is the classic example where the two overlap: the same clone of B cells is called CLL when circulating in blood and Small Lymphocytic Lymphoma (SLL) when sitting in a lymph node
Sources: Goldman-Cecil Medicine 2-vol set | Robbins, Cotran & Kumar Pathologic Basis of Disease | Sabiston Textbook of Surgery | Harrison's Principles of Internal Medicine 22E | Textbook of Family Medicine 9e
This is a shared conversation. Sign in to Orris to start your own chat.